Heterocyclic inhibitors of pde4
AssigneeKalypsys, Inc.
InventorsSteven P. Govek, Guy Oshiro, Stewart A. Noble, James W. Malecha, Andrew K. Shiau
Life of this patent
Estimating the term…
Abstract
The present invention is directed to potent and selective heterocyclic compounds, useful as inhibitors of phosphodiesterase 4 (PDE4), compositions comprising the same, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of PDE4 activity are also provided, as well as methods for the treatment of inflammatory diseases and other diseases in which PDE4 or one of its isoforms may play a role.
Claims14
A compound selected from the group consisting of Examples 1 to 17 and 20 to 29 for use as a medicament.
A compound selected from the group consisting of Examples 1 to 29 for use in the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the inhibition of PDE4.
A pharmaceutical composition comprising a compound selected from the group consisting of Examples 1 to 17 and 20 to 29, together with a pharmaceutically acceptable carrier.
The pharmaceutical composition comprising a compound selected from the group consisting of Examples 1 to 29, together with a pharmaceutically acceptable carrier, useful for the treatment or prevention of a PDE4-mediated disease.
A method of inhibition of PDE4 comprising contacting PDE4 with a compound selected from the group consisting of Examples 1 to 29.
A method of treatment of a PDE4-mediated disease comprising the administration of a therapeutically effective amount of a compound selected from the group consisting of Examples 1 to 29 to a patient in need thereof.
A method of treatment of a PDE4-mediated disease comprising the administration of:
- a. a therapeutically effective amount of a compound selected from the group consisting of Examples 1 to 29;
- and
- b. another therapeutic agent.
Dependencies are inferred from the claim text.